First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...
The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...
1d
Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Genmab (GMAB – Research Report). The associated price target ...
Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...
Johnson & Johnson's Rybrevant and Lazcluze combination shows significant overall survival benefits over Tagrisso in the ...
Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...
Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors
Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® ...
Yuhan Corp., Oscotec Inc. and Genosco Inc. were three companies with Asian ties to reap benefit from Johnson & Johnson’s stellar top-line Mariposa study results, wherein J&J’s Rybrevant ...
Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback